Prostate Cancer

Phase III Advanced Cancer Treatment Study Enrollment Completed

Published in Cancer Weekly, June 20th, 2000

Atrix Laboratories (ATRX), Fort Collins, Colorado, announced that it has completed the enrollment of patients in its Phase III human clinical trial for advanced prostate cancer.

The therapy uses the company's innovative Atrigel drug delivery system to administer a 30-day sustained release of leuprolide acetate subcutaneously, an easier and more patient-friendly route of administration than the deep intramuscular injections currently used.

A total of 120 patients are now enrolled in the multi-center, Phase III clinical trial, which is expected to be completed by the end of 2000. The company plans to submit a New Drug Application (NDA) for the new...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-06-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry